

Daftar Pustaka

1. Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, et al. High-sensitivity C-reactive Protein and Cardiovascular Disease: A resolute belief or an elusive link?. *J Am Coll Cardiol*. 2013; 62(5): 397–408
2. Depkes. Penyakit Jantung Penyebab Kematian Tertinggi, Kemenkes Ingatkan CERDIK].2017.[cited 2017 Desember 10] Available from: <http://www.depkes.go.id/article/view/17073100005/penyakit-jantung-penyebab-kematian-tertinggi-kemenkes-ingatkan-cerdik-.html>
3. Fuster V, Kelly BB. Global Epidemiology of Cardiovascular Disease. *Promot Cardiovasc Heal Dev World A Crit Chall to Achieve Glob Heal*. 2010. p. 25–34.
4. Kamath DY, Xavier D, Sigamani A, Pais P. High Sensitivity C-reactive Protein (hsCRP) & Cardiovascular Disease: An Indian perspective. *Indian J Med Res*. 2015; 142(9). 261–8.
5. Sullivan SO. Statins : A review of benefits and risks. *TSMJ*. 2007; 8. 52–6.
6. Stancu C, Sima A. Statins: Mechanism of Action and Effects. *J Cell Mol Med*. 2001;5(4). 378–87
7. Komosinska-Vassev K, Olczyk P, Kazmierczak J, Mencner L, Olczyk K. Bee pollen: Chemical Composition and Therapeutic Application. *Evidence-Based Complement Altern*. 2015;1–6
8. National Heart Lung and Blood Institute. At a Glance: Atherosclerosis. 2009. [Cited 2018 January 2], Available from https://www.nhlbi.nih.gov/files/docs/public/heart/atherosclerosis_atglance.pdf..
9. S M, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) can C-reactive protein be used to target statin therapy in primary prevention? *Am J Cardiol*. 2006;97(2A):33A–41A.
10. Cipla. Essential information in brief: Dyslipidemia. *Essent Ser*. 2005; [cited 2017 Desember 10] Available from: <https://ciplamed.com/topics/48>
11. Yelle, Dominique. ATHEROSCLEROSIS. *New english journal Med*. 2005;352: 1685–95.
12. Ridker PM. Inflammation, Aspirin, and The Risk of Cardiovascular Disease in Apparently Healthy Men. *New english journal Med*. 1997;336: 973–9.
13. Ridker P. Comparison of C-reactive Protein and Low-Density Lipoprotein Cholesterol Levels in The Prediction of First Cardiovascular Events. *New english journal Med*. 2002;347: 1557–65.

14. Goszcz K, Deakin SJ, Duthie GG, Stewart D, Leslie SJ, Megson IL. Antioxidants in Cardiovascular Therapy: Panacea or False Hope? *Front Cardiovasc Med*. 2015;2(July):1–22.
15. Hung CH, Chan SH, Chu PM, Tsai KL. Quercetin is a Potent Anti-atherosclerotic Compound by Activation of SIRT1 Signaling Under oxLDL Stimulation. *Mol Nutr Food Res*. 2015;59(10):1905–17.
16. Pompella A, Visvikis A, Paolicchi A, Tata V De, Casini AF. The Changing Faces Of Glutathione, A Cellular Protagonist. *Biochem Pharmacol*. 2003 Oct 15 [cited 2018 Jun 26];66(8):1499–503. Available from: <https://www.sciencedirect.com/science/article/abs/pii/S0006295203005045>
17. DEXA MEDICA. SIMVASTATIN. 2018. [cited 2018 Jun 26] Available from: <http://www.dexa-medica.com/our-product/prescriptions/ogb/Simvastatin>
18. F.A. Davis. Simvastatin. [cited 2018 Jun 26] 2015. Available from: <https://davisplus.fadavis.com/3976/meddeck/pdf/Simvastatin.pdf>.
19. Kostner KM, März W, Kostner GM. When Should We Measure Lipoprotein (A)? *Eur Heart J*. 2013;34(42):3268–76.
20. Marcus J, Sarnak MJ, Menon V. Homocysteine Lowering And Cardiovascular Disease Risk: Lost In Translation. *Can J Cardiol*. 2007;23(9):707–10.
21. Widiastuti N.P., *et al*. Pengaruh Pemberian Vitamin E, Isolat Andrografolid Serta Kombinasi Isolat Andrografolid dan Vitamin E Dalam Pencegahan Terbentuknya Plak Lemak Pada Aorta Tikus. *Jurnal Farmasi Udayana*. 2016; 5(1):4
22. Hengki Y. Pengaruh *Bee Pollen* Terhadap Kadar HDL dan LDL Tikus Jantan Galur Wistar yang Diinduksi Pakan Tinggi Lemak. 2016;62